FIG. 2.
Evaluation of skeletal muscle transduction by AAV variants, using biophotonic imaging. Skeletal muscle transduction of (A) Q263AT265-luciferase and N705AV708AT716N-luciferase vectors was examined on days 3, 7, 21, 28, and 42 postinjection. (B) Q263A-luciferase and T265-luciferase vectors were examined on days 7, 14, 28, 42, 100, and 170 postinjection. (C) AAV1-, AAV2-, AAV3b-, and SASTG-luciferase vectors were examined on days 3, 7, 14, and 21. For each experiment in (A), (B), and (C) each limb (n=6 limbs per group) was injected with 1×109 genome particles in each gastrocnemius muscle. Data are expressed as relative light units per region of interest (RLU/ROI). (D) Comparison of skeletal muscle transduction of AAV3, AAV3.1, and SASTG, using in vivo biophotonic imaging of hind leg injections. Increasing wavelength reflects greater luminescence. Color images available online at www.liebertonline.com/hum